Global /United States /Healthcare /Medical Instruments & Supplies /RGEN
chevron_leftBack

Repligen Corp.

RGEN
NASDAQ: RGEN Delayed
141.40USD 1.8%
As of 24 April 2025, Repligen Corp. has a market cap of $7.94B USD, ranking #2033 globally and #708 in the United States. It ranks #178 in the Healthcare sector, and #20 in the Medical Instruments & Supplies industry.
Global Rank
2033
Country Rank
708
Sector Rank
178
Industry Rank
20
Key Stats
Market Cap
$7.94BUSD
Enterprise Value
$7.87BUSD
Revenue (TTM)
$634.44MUSD
EBITDA (TTM)
$107.3MUSD
Net Income (TTM)
-$25.51MUSD
EBITDA Margin
17%
Profit Margin
-4%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Olivier Loeillot open_in_new
Employees
1,778
Founded
1981
Website
repligen.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.8% 7.1% 1% -15% -1.9% -10%
Upcoming Earnings
Earnings Date
Tue, Apr 29
Earnings Time
sunny Before Open
EPS Estimate
$0.3500 25% yoy
Revenue Estimate
$163.46M 8% yoy

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
RGEN
Repligen Corp
ISIN: US7599161095
Shares Out.:
56.149M1 Shares Float: 53.024M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
141.40 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Repligen Corp.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Medical Instruments & Supplies (United States)
Name
Market Cap diff.
Intuitive Surgical, Inc.
ISRG
$174.81B
2K%
Becton, Dickinson and Co.
BDX
$58.09B
631%
ResMed Inc.
RMD
$31.44B
296%
The Cooper Companies, Inc.
COO
$16.17B
104%
West Pharmaceutical Services, Inc.
WST
$15.77B
99%
Industry: Medical Instruments & Supplies (Global)
Name
Market Cap diff.
EssilorLuxottica Société anonyme
EL
$133.72B
117.51B EUR
2K%
Alcon Inc.
ALC
$46.68B
38.55B CHF
488%
HOYA Corp.
7741
$38.56B
5.49T JPY
385%
Terumo Corp.
4543
$28.62B
4.08T JPY
260%
Coloplast A/S
COLO-B
$24.61B
161.44B DKK
210%